CN1203180C - 来自脑膜炎奈瑟氏球菌的basb006多核苷酸和多肽 - Google Patents

来自脑膜炎奈瑟氏球菌的basb006多核苷酸和多肽 Download PDF

Info

Publication number
CN1203180C
CN1203180C CNB998077712A CN99807771A CN1203180C CN 1203180 C CN1203180 C CN 1203180C CN B998077712 A CNB998077712 A CN B998077712A CN 99807771 A CN99807771 A CN 99807771A CN 1203180 C CN1203180 C CN 1203180C
Authority
CN
China
Prior art keywords
gly
polypeptide
ala
asn
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998077712A
Other languages
English (en)
Chinese (zh)
Other versions
CN1336957A (zh
Inventor
J·通纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1336957A publication Critical patent/CN1336957A/zh
Application granted granted Critical
Publication of CN1203180C publication Critical patent/CN1203180C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
CNB998077712A 1998-04-24 1999-04-20 来自脑膜炎奈瑟氏球菌的basb006多核苷酸和多肽 Expired - Fee Related CN1203180C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808866.9A GB9808866D0 (en) 1998-04-24 1998-04-24 Novel compounds
GB9808866.9 1998-04-24

Publications (2)

Publication Number Publication Date
CN1336957A CN1336957A (zh) 2002-02-20
CN1203180C true CN1203180C (zh) 2005-05-25

Family

ID=10830985

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998077712A Expired - Fee Related CN1203180C (zh) 1998-04-24 1999-04-20 来自脑膜炎奈瑟氏球菌的basb006多核苷酸和多肽

Country Status (8)

Country Link
US (3) US6696062B1 (enExample)
EP (2) EP1071783A2 (enExample)
JP (2) JP4718009B2 (enExample)
CN (1) CN1203180C (enExample)
AU (1) AU3928499A (enExample)
CA (1) CA2326375A1 (enExample)
GB (1) GB9808866D0 (enExample)
WO (1) WO1999055873A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813930A (pt) * 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2615362T3 (es) * 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
RU2364418C2 (ru) * 2002-08-02 2009-08-20 ГлаксоСмитКлайн Байолоджикалз с.а. ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
MX2010012999A (es) 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
CA2792691A1 (en) 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example, neisserial, infection or disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
AU695869B2 (en) 1993-04-06 1998-08-27 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
JPH08508889A (ja) 1993-06-07 1996-09-24 アムジエン・インコーポレーテツド ハイブリッドレセプター分子
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
EP0821737A4 (en) 1995-04-21 2005-01-19 Human Genome Sciences Inc NUCLEOTIDE SEQUENCE OF THE GENOME HAEMOPHILUS INFLUENZAE RD, THE FRAGMENTS THEREOF, AND ITS APPLICATIONS
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
DE69708318T3 (de) * 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
BR9813930A (pt) * 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
GB9808734D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US7666988B1 (en) * 1999-03-12 2010-02-23 Glaxosmithkline Biologicals S.A. BASB082 Polypeptides
GB0025171D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
ES2615362T3 (es) * 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos

Also Published As

Publication number Publication date
EP2360260A1 (en) 2011-08-24
WO1999055873A2 (en) 1999-11-04
EP1071783A2 (en) 2001-01-31
JP2010166920A (ja) 2010-08-05
US7419824B2 (en) 2008-09-02
CN1336957A (zh) 2002-02-20
US20100196409A1 (en) 2010-08-05
JP2002512800A (ja) 2002-05-08
US6696062B1 (en) 2004-02-24
JP4718009B2 (ja) 2011-07-06
US20040137530A1 (en) 2004-07-15
GB9808866D0 (en) 1998-06-24
CA2326375A1 (en) 1999-11-04
AU3928499A (en) 1999-11-16
WO1999055873A3 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
CN1201818C (zh) 疫苗
CN1336957A (zh) 来自脑膜炎奈瑟氏球菌的basb006多核苷酸和多肽
CN1367830A (zh) 癌症相关抗原及其应用
CN1284965A (zh) 脑膜炎奈瑟氏球菌的新表面蛋白
CN1944652A (zh) B组链球菌抗原
CN1309707A (zh) 来自脑膜炎奈瑟氏球菌的basb029多核苷酸和多酞
CN1166858A (zh) tagA基因以及检测消化性溃疡和胃癌易感性的方法
CN1249233C (zh) 肺炎衣原体表面蛋白
CN1350585A (zh) 脑膜炎奈瑟氏菌多肽basb052
CN1245419C (zh) 脑膜炎奈瑟氏球菌(Neisseria meningitidis)的多核苷酸和多肽BASB033及其用途
CN1322249A (zh) 脑膜炎奈瑟氏球菌抗原性多肽、相应多核苷酸和保护性抗体
CN1204253C (zh) 奈瑟氏球菌乳铁蛋白结合蛋白
CN1906210A (zh) 表面定位的空肠弯曲杆菌多肽
CN1210401C (zh) 源自粘膜炎莫拉氏菌的化合物
CN1185255C (zh) 检测梅毒密螺旋体的组合物和方法
CN1198931C (zh) 粘膜炎莫拉氏菌basb034多肽及应用
CN1375006A (zh) 新型化合物
CN1370231A (zh) Casb618多核苷酸和多肽及其用途
CN1351661A (zh) 新化合物
CN1420930A (zh) 新颖的化合物
CN1545552A (zh) 基因和蛋白质及它们的用途
CN1344322A (zh) 脑膜炎奈瑟氏菌basb055多核苷酸和多肽及其用途
CN1514879A (zh) 粘膜炎莫拉氏菌(布兰汉氏菌)抗原
CN1391610A (zh) 粘膜炎莫拉氏菌的basb118多肽和多核苷酸
CN1377411A (zh) 粘膜炎莫拉氏菌的basb119多肽和多核苷酸

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050525

Termination date: 20140420